Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntelliAM AI Regulatory News (INT.PL)

Share Price Information for IntelliAM AI (INT.PL)

Share Price is delayed by 15 minutes
Get Live Data
80.00    0.00 (0.00%)
Bid:
70.00
Ask:
90.00
Spread: 20.00 (28.571%)
Market Cap: £15.68m
INT.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday IntelliAM AI Share Chart

Move from Access to Apex segment

27 Oct 2025 07:35

RNS Number : 9190E
IntelliAM AI PLC
27 October 2025
 

27 October 2025

 

IntelliAM AI PLC

Admission to the Apex segment of the AQSE Growth Market

 

IntelliAM AI (AQSE: INT) ("IntelliAM" or the "Company"), the specialist in AI-driven asset management, empowering industrial operations to cut costs and enhance productivity, is pleased to announce that it is eligible for its ordinary shares to commence trading on the Apex segment of the Aquis Stock Exchange ("AQSE") with effect from 3 November 2025.

 

The Apex segment caters for larger, more established businesses, and enforces stricter eligibility criteria to encourage greater liquidity and transparency.

 

IntelliAM, which first listed on AQSE in July 2024, satisfies the qualifying criteria for its ordinary shares to trade on the Apex segment, including:

 

· A minimum market capitalisation of £10 million.

· At least 2 active market makers.

· A minimum 2 years' trading history.

· High standards of Corporate Governance Code compliance and disclosures.

 

At the date of this announcement, shares representing 22.9% of the Company's issued share capital are in public hands. Notwithstanding the current free float, Aquis has approved a derogation to the Apex free float requirement of 25%, given the institutional investor support the Company has received since IPO, the significant strategic progress recently announced, including a co-development Partnership Agreement with a global engineering manufacturer (as announced 24 September 2025) and the major expansion of its commercial partnership with Hovis Limited (as announced 1 October 2025) and the immaterial variance of only 2.1% below the 25% threshold requirement.

 

Tom Clayton, Founder and CEO of IntelliAM AI plc, said:

"I am delighted to now be part of the Apex segment on the Aquis Growth Market. Our move to the Apex segment will provide further visibility to our existing and prospective investors, and we welcome the increased emphasis on transparency, liquidity, and corporate governance, which is entirely aligned with IntelliAM's strategy."

 

David Stevens, CEO Aquis Exchange, said:

"We are delighted to see IntelliAM's move up to the Apex segment of the Aquis Stock Exchange Growth Market. It's fantastic to see how the company has progressed so far, and I am proud that Aquis can offer a tailored experience for growth companies that allows for increased exposure to investors at appropriate stages."

 

Enquiries:

 

 

IntelliAM AI plc

Tom Clayton, Chief Executive Officer

Daud Khan, Chief Financial Officer

 

 

 

 

+44 114 299 5007

Oberon Capital - AQSE Corporate Adviser and Broker

Nick Lovering

Adam Pollock

Mike Seabrook

 

+44 203 179 5300

Square1 Consulting - Financial PR

David Bick

+44 207 929 5599

+44 7831 381201

 

Ends

 

About IntelliAM AI:

 

IntelliAM AI plc specializes in developing AI-powered software solutions for the manufacturing industry. The IntelliAM platform harnesses the power of machine learning to optimize industrial asset management, improve productivity, and reduce operational costs. For more information, visit www.intelliam.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXPPGMPUUPAUMM
12
Date   Source Headline
8th Jul 20267:00 amRNSNew Customer Wins
7th Jul 20267:07 amRNSFundraising to augment growth in US operations
6th Jul 20267:30 amRNSLaunch of Investor Hub
20th May 20267:00 amRNSUS Expansion and CRO Appointment
16th Apr 20267:00 amRNSTrading Update
1st Apr 20267:00 amRNSAcquisition of RBM Lubrications
19th Mar 20267:00 amRNSAppointment of Corporate Adviser and Broker
6th Jan 20267:00 amRNSOrders from New Customer in Frozen Food Vertical
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
10th Dec 20258:17 amRNSHolding(s) in Company
2nd Dec 20258:38 amRNSResult of Oversubscribed WRAP Retail Offer
25th Nov 20257:05 amRNSContract
25th Nov 20257:00 amRNSHalf-year Financial Report
24th Nov 202512:35 pmRNSWRAP Retail Offer
24th Nov 202512:30 pmRNSPlacing and Retail Offer
4th Nov 20257:00 amRNSFirst Half Trading Statement
27th Oct 20257:35 amRNSMove from Access to Apex segment
3rd Oct 20253:45 pmRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSContract
24th Sep 20257:00 amRNSContract
12th Sep 20257:00 amRNS-RManufacturing Tech Award 2025
9th Sep 202512:33 pmRNSResult of Annual General Meeting
4th Sep 20257:00 amRNSDirectorate Change
12th Aug 20257:00 amRNSAnnual Financial Report
8th Aug 20253:00 pmRNSHolding(s) in Company
25th Jul 20257:00 amRNS-RAppointment of Vice President of Sales
7th Jul 20257:00 amRNSFinal Results
3rd Jul 20257:00 amRNSStrategic Partnership Agreement with CTC in USA
2nd Jul 20257:00 amRNSContract
1st Jul 20257:00 amRNSDirectorate Change
27th May 20257:00 amRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSTrading Update
2nd May 20257:00 amRNSDirectorate Change
26th Mar 20257:00 amRNS-RSenior Management Team Strengthened
20th Mar 20252:25 pmRNSDirector/PDMR Shareholding
24th Feb 20251:00 pmRNSDeath of a Non-Executive Director
13th Jan 20257:00 amRNSDirectorate Change
18th Dec 20243:57 pmRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSDirector/PDMR Shareholding
16th Dec 20247:00 amRNSDirector/PDMR Shareholding
12th Dec 20244:51 pmRNSDirector/PDMR Shareholding
11th Dec 20247:00 amRNSLetter of Intent Signed
9th Dec 20247:00 amRNSHalf-year Report
6th Nov 20241:13 pmRNSResult of Annual General Meeting
10th Oct 20243:30 pmRNSPosting of Annual Report and Notice of AGM
25th Sep 20247:00 amRNSAnnual Financial Report
16th Sep 20247:00 amRNSContract
7th Aug 20247:00 amRNSContract
11th Jul 20247:00 amRNSContract
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.